Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Rheumatic Disease ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Systemic autoimmune disease as a cause of death: mortality burden and comorbidities.Rheumatology. 2021; 60: 1321-1330
- Cardiovascular involvement in systemic rheumatic diseases: an integrated view for the treating physicians.Autoimmun Rev. 2018; 17: 201-214
- Microvascular heart involvement in systemic autoimmune diseases: The purinergic pathway and therapeutic insights from the biology of the diseases.Autoimmun Rev. 2019; 18: 317-324
- Myocarditis in systemic immune-mediated diseases.in: Caforio A.L.P. Myocarditis: pathogenesis, diagnosis and treatment. Springer International Publishing, 2020: 195-221https://doi.org/10.1007/978-3-030-35276-9_11
- Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin.Arthritis Care Res (Hoboken). 2011; 63: 178-183
- The inextricable link between atherosclerosis and prototypical inflammatory diseases rheumatoid arthritis and systemic lupus erythematosus.Arthritis Res Ther. 2009; 11: 217
- Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis.Circ J. 2009; 73: 977-985
- Cardiorheumatology: cardiac involvement in systemic rheumatic disease.Nat Rev Cardiol. 2015; 12: 168-176
- Common inflammatory mediators orchestrate pathophysiological processes in rheumatoid arthritis and atherosclerosis.Rheumatology (Oxford). 2009; 48: 11-22
- Inflammatory markers in patients with coronary artery disease with and without inflammatory rheumatic disease.Rheumatology (Oxford). 2010; 49: 1118-1127
- Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases.Eur Heart J. 2016; 37: 1799-1806
- Coronary microvascular dysfunction: mechanisms and functional assessment.Nat Rev Cardiol. 2015; 12: 48-62
- Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction.Circulation. 2015; 131: 550-559
- Multiple common comorbidities produce left ventricular diastolic dysfunction associated with coronary microvascular dysfunction, oxidative stress, and myocardial stiffening.Cardiovasc Res. 2018; 114: 954-964
- Inflammation and coronary microvascular dysfunction in autoimmune rheumatic diseases.Int J Mol Sci. 2019; 20: 5563
- Inflammation is related to coronary flow reserve detected by positron emission tomography in asymptomatic male twins.J Am Coll Cardiol. 2011; 57: 1271-1279
- Association between serum total antioxidant status and coronary microvascular functions in patients with SLE.Echocardiography. 2012; 29: 1218-1223
- uPA/uPAR signaling in rheumatoid arthritis: Shedding light on its mechanism of action.Pharmacol Res. 2018; 134: 31-39
- Plasma soluble urokinase plasminogen activator receptor (suPAR) levels in systemic lupus erythematosus.Biomarkers. 2012; 17: 758-763
- Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease.Atherosclerosis. 2015; 239: 55-60
- Pathophysiology of systemic sclerosis: current understanding and new insights.Expert Rev Clin Immunol. 2019; 15: 753-764
- The Fra-2 transgenic mouse model of systemic sclerosis.Vasc Pharmacol. 2013; 58: 194-201
- Cardiomyopathy in murine models of systemic sclerosis.Arthritis Rheumatol. 2015; 67: 508-516
- Transcription factor fos-related antigen-2 induces progressive peripheral vasculopathy in mice closely resembling human systemic sclerosis.Circulation. 2009; 120: 2367-2376
- Reduced lymphatic reserve in heart failure with preserved ejection fraction.J Am Coll Cardiol. 2020; 76: 2817-2829
- Lymphatic function in autoimmune diseases.Front Immunol. 2019; 10: 519
- Lymphatic and blood vessels in scleroderma skin, a morphometric analysis.Hum Pathol. 2010; 41: 366-374
- Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis.Nat Rev Rheumatol. 2018; 14: 94-106
- Cardiac autoimmunity: myocarditis.Adv Exp Med Biol. 2017; 1003: 187-221
- Lethal immunoglobulins: autoantibodies and sudden cardiac death.Autoimmun Rev. 2019; 18: 415-425
- Autoimmune myocarditis, valvulitis, and cardiomyopathy.Curr Protoc Immunol. 2013; (Chapter 15:Unit 15.14): 1-51
- Autoantibodies and cardiovascular dysfunction: cause or consequence?.Curr Heart Fail Rep. 2014; 11: 500-508
- Cryptic epitope identified in rat and human cardiac myosin S2 region induces myocarditis in the Lewis rat.J Immunol. 2004; 172: 3225-3234
- Consequences of unlocking the cardiac myosin molecule in human myocarditis and cardiomyopathies.Autoimmunity. 2008; 41: 442-453
- Cardiac myosin-Th17 responses promote heart failure in human myocarditis.JCI Insight. 2016; 1: 85851
- β1-adrenoreceptor autoantibodies in heart failure: physiology and therapeutic implications.Circ Heart Fail. 2020; 13: e006155
- Autoantibodies specifically against β1 adrenergic receptors and adverse clinical outcome in patients with chronic systolic heart failure in the β-blocker era: the importance of immunoglobulin G3 subclass.J Card Fail. 2016; 22: 417-422
- Autoantibodies to angiotensin and endothelin receptors in systemic sclerosis induce cellular and systemic events associated with disease pathogenesis.Arthritis Res Ther. 2014; 16: R29
- Systemic lupus erythematosus.Ann Intern Med. 2020; 172: ITC81-ITC96
- Management strategies and future directions for systemic lupus erythematosus in adults.Lancet. 2019; 393: 2332-2343
- Cardiac manifestations of systemic lupus erythematosus.Rheum Dis Clin North Am. 2014; 40: 51-60
- Lupus Myocarditis: Initial Presentation and Longterm Outcomes in a Multicentric Series of 29 Patients.J Rheumatol. 2017; 44: 24-32
- The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients.Am J Med. 1975; 58: 243-264
- The diagnostic role of cardiac magnetic resonance imaging in detecting myocardial inflammation in systemic lupus erythematosus. Differentiation from viral myocarditis.Lupus. 2013; 22: 34-43
- Cardiac pathology of systemic lupus erythematosus.J Clin Pathol. 2009; 62: 584-592
- Differential associations of chronic inflammatory diseases with incident heart failure.JACC: Heart Fail. 2020; 8: 489-498
- Heart involvement in systemic lupus erythematosus: a systemic review and meta-analysis.Clin Rheumatol. 2016; 35: 2437-2448
- Early echocardiographic detection of left ventricular diastolic dysfunction in patients with systemic lupus erythematosus asymptomatic for cardiovascular disease.Clin Exp Med. 2020; 20: 11-19
- Aortic stiffness is associated with left ventricular diastolic dysfunction in systemic lupus erythematosus: a controlled transesophageal echocardiographic study.Clin Cardiol. 2014; 37: 83-90
- Prevalence, distribution and clinical correlates of myocardial fibrosis in systemic lupus erythematosus: a cardiac magnetic resonance study.Lupus. 2016; 25: 573-581
- SLICC/ACR damage index independently associated with left ventricular diastolic dysfunction in patients with systemic lupus erythematosus.Lupus. 2012; 21: 1057-1062
- Soluble ST2 and CXCL-10 may serve as biomarkers of subclinical diastolic dysfunction in SLE and correlate with disease activity and damage.Lupus. 2020; 29: 1430-1437
- Heart failure in systemic lupus erythematosus.Trends Cardiovasc Med. 2018; 28: 187-197
- Autoimmune-mediated congenital heart block.Best Pract Res Clin Obstet Gynaecol. 2020; 64: 41-51
- Connective-tissue disease, antibodies to ribonucleoprotein, and congenital heart block.N Engl J Med. 1983; 309: 209-212
- Congenital complete heart block and maternal connective tissue disease.Int J Cardiol. 2006; 112: 153-158
- Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela.J Am Coll Cardiol. 2001; 37: 238-242
- Hydroxychloroquine to prevent recurrent congenital heart block in fetuses of Anti-SSA/Ro-positive mothers.J Am Coll Cardiol. 2020; 76: 292-302
- The pathogenesis of rheumatoid arthritis.N Engl J Med. 2011; 365: 2205-2219
- Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis.Circulation. 2003; 107: 1303-1307
- Cardiovascular morbidity and mortality in rheumatoid arthritis.Am J Med. 2008; 121: S9-S14
- Outcomes of acute myocardial infarction in patients with rheumatoid arthritis.Am J Med. 2020; 133: 1168-1179.e4
- The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years.Arthritis Rheum. 2005; 52: 412-420
- The heart in rheumatoid arthritis (rheumatoid disease). A clinical and pathological study of sixty-two cases.Ann Intern Med. 1963; 58: 102-123
- A 73-year-old woman with rheumatoid arthritis and shortness of breath.Arthritis Rheum. 2008; 59: 892-899
- Diffuse myocardial fibrosis and inflammation in rheumatoid arthritis: insights from CMR T1 mapping.JACC Cardiovasc Imaging. 2015; 8: 526-536
- Advanced myocardial tissue characterisation by a multi-component CMR protocol in patients with rheumatoid arthritis.Eur Radiol. 2017; 27: 4639-4649
- Systemic sclerosis.The Lancet. 2017; 390: 1685-1699
- Primary myocardial disease in scleroderma-a comprehensive review of the literature to inform the UK Systemic Sclerosis Study Group cardiac working group.Rheumatology (Oxford). 2017; 56: 882-895
- Pulmonary hypertension in systemic sclerosis.Semin Arthritis Rheum. 2011; 41: 19-37
- Pulmonary hypertension in systemic sclerosis: different phenotypes.Eur Respir Rev. 2017; 26https://doi.org/10.1183/16000617.0056-2017
- High prevalence of occult left heart disease in scleroderma-pulmonary hypertension.Eur Respir J. 2013; 42: 1083-1091
- Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction.Pulm Circ. 2017; 7: 409-420
- Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: derivation and internal validation.Autoimmun Rev. 2020; 19: 102507
- Assessment of left and right ventricular diastolic function in patients with systemic sclerosis.Kardiol Pol. 2008; 66 ([discussion: 277-278]): 269-276
- Left ventricular diastolic dysfunction predicts mortality in patients with systemic sclerosis.J Am Coll Cardiol. 2018; 72: 1804-1813
- Blunted coronary flow reserve in systemic sclerosis.Rheumatology (Oxford). 2004; 43: 505-509
- Diastolic abnormalities in systemic sclerosis: evidence for associated defective cardiac functional reserve.Ann Rheum Dis. 1996; 55: 455-460
- Nailfold avascular score and coronary microvascular dysfunction in systemic sclerosis: a newsworthy association.Autoimmun Rev. 2019; 18: 177-183
- Unique Abnormalities in right ventricular longitudinal strain in systemic sclerosis patients.Circ Cardiovasc Imaging. 2016; 9https://doi.org/10.1161/CIRCIMAGING.115.003792
- Left ventricular dysfunction assessed by speckle-tracking strain analysis in patients with systemic sclerosis: relationship to functional capacity and ventricular arrhythmias.Arthritis Rheum. 2011; 63: 3969-3978
- Assessment of myocardial fibrosis and microvascular damage in systemic sclerosis by magnetic resonance imaging and coronary angiotomography.Rheumatology (Oxford). 2015; 54: 647-654
- Silent myocarditis in systemic sclerosis detected by cardiovascular magnetic resonance using Lake Louise criteria.BMC Cardiovasc Disord. 2017; 17: 187
- Scleroderma and primary myocardial disease.in: StatPearls. StatPearls Publishing, 2020 (Available at:) (Accessed July 22, 2020)
- Primary myocardial involvement in systemic sclerosis: evidence for a microvascular origin.Clin Exp Rheumatol. 2010; 28: S48-S53
- Association of myositis and myocarditis in progressive systemic sclerosis.Arthritis Rheum. 1981; 24: 662-668
- Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis.Rheumatology (Oxford). 2020; https://doi.org/10.1093/rheumatology/kez658
- The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis.Rheumatology (Oxford). 2003; 42: 534-540
- Human autoantibodies reveal titin as a chromosomal protein.J Cell Biol. 1998; 141: 321-333
- Involvement of functional autoantibodies against vascular receptors in systemic sclerosis.Ann Rheum Dis. 2011; 70: 530-536
- Progressive loss of lymphatic vessels in skin of patients with systemic sclerosis.J Rheumatol. 2011; 38: 297-301
- Update on eosinophilic granulomatosis with polyangiitis.Allergol Int. 2019; 68: 430-436
- The heart in vasculitis.Rheum Dis Clin North Am. 2014; 40: 11-26
- Antineutrophil cytoplasmic antibodies and organ-specific manifestations in eosinophilic granulomatosis with polyangiitis: a systematic review and meta-analysis.J Allergy Clin Immunol Pract. 2021; 9: 445-452.e6
- Eosinophilic myocarditis demonstrated using cardiac magnetic resonance imaging in a patient with eosinophilic granulomatosis with polyangiitis (churg-strauss disease).Cureus. 2018; 10: e2792
- Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort.Arthritis Rheum. 2013; 65: 270-281
- Cardiac involvement in eosinophilic granulomatosis with polyangitis (Churg Strauss) (RCD code: I-3A.7a).J Rare Cardiovasc Dis. 2014; 1: 91-95
- Cardiac involvement in Churg-Strauss syndrome.Arthritis Rheum. 2010; 62: 627-634
- [Cardiac involvement in Churg-Strauss syndrome].G Ital Cardiol (Rome). 2015; 16: 493-500
- A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients.Ann Rheum Dis. 2013; 72: 1011-1017
- Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.J Allergy Clin Immunol. 2019; 143: 2170-2177
- 2012 Revised international chapel hill consensus conference nomenclature of vasculitides.Arthritis Rheum. 2013; 65: 1-11
- Cardiac involvement in granulomatosis with polyangiitis.J Rheumatol. 2015; 42: 1209-1212
- The Five-Factor Score revisited: assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group (FVSG) cohort.Medicine (Baltimore). 2011; 90: 19-27
- Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis.Arthritis Rheum. 2012; 64: 542-548
- Granulomatosis with polyangiitis with myocarditis and ventricular tachycardia.Case Rep Med. 2017; 2017: 6501738
- Acute myocarditis in a patient with newly diagnosed granulomatosis with polyangiitis.Case Rep Cardiol. 2015; 2015: 134529
- Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis.N Engl J Med. 2014; 371: 1771-1780
- Echocardiographic findings in patients with wegener granulomatosis.Mayo Clinic Proc. 2005; 80: 1435-1440
- One year in review 2015: Sjögren’s syndrome.Clin Exp Rheumatol. 2015; 33: 259-271
- Primary sjögren’s syndrome and the risk of acute myocardial infarction: a nationwide study.Acta Cardiol Sin. 2013; 29: 124-131
- Cardiovascular disease risk burden in primary Sjögren’s syndrome: results of a population-based multicentre cohort study.J Intern Med. 2015; 278: 185-192
- Cardiac manifestations in primary Sjögren’s syndrome.Ann Rheum Dis. 1996; 55: 450-454
- Is the heart affected in primary Sjögren’s syndrome? An echocardiographic study.Clin Exp Rheumatol. 2008; 26: 109-112
- Assessment of left ventricular functions in patients with Sjögren’s syndrome using tissue Doppler echocardiography.Int J Rheum Dis. 2013; 16: 425-429
- Myocarditis and primary Sjögren’s syndrome.Lancet. 1999; 354: 128-129
- Primary Sjögren’s syndrome complicated with cryoglobulinemic glomerulonephritis, myocarditis, and multi-organ involvement.J Formos Med Assoc. 2004; 103: 707-710
- Autoimmune congenital heart block and primary Sjögren’s syndrome: characterisation and outcomes of 49 cases.Clin Exp Rheumatol. 2020; 38 (4): 95-102
- Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease.Eur Heart J. 2017; 38: 2649-2662
- Pathophysiology and clinical management of cardiac sarcoidosis.Nat Rev Cardiol. 2015; 12: 278-288
- Pathological studies on sarcoidosis autopsy. II. Early change, mode of progression and death pattern.Acta Pathol Jpn. 1993; 43: 377-385
- Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations.Arch Pathol Lab Med. 1995; 119: 167-172
- Clinical characteristics of patients in a case control study of sarcoidosis.Am J Respir Crit Care Med. 2001; 164: 1885-1889
- Racial difference in cardiac sarcoidosis incidence observed at autopsy.Sarcoidosis. 1994; 11: 26-31
- Diagnosis and treatment of cardiac sarcoidosis.Heart. 2016; 102: 184-190
- Ventricular tachyarrhythmia as a primary presentation of sarcoidosis.Europace. 2008; 10: 760-766
- Refractory ventricular tachycardia secondary to cardiac sarcoid: Electrophysiologic characteristics, mapping, and ablation.Heart Rhythm. 2006; 3: 924-929
- Cardiovascular risk in patients with psoriatic arthritis.Int J Rheumatol. 2012; 2012
- Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death.Arthritis Rheum. 1997; 40: 1868-1872
- Mortality in psoriatic arthritis – a single-center study from the UK.J Rheumatol. 2010; 37: 2141-2144
- Cardiovascular morbidity and mortality in ankylosing spondylitis and psoriatic arthritis.Best Pract Res Clin Rheumatol. 2018; 32: 369-389
- Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality.Ann Intern Med. 2015; 163: 409-416
- Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis.Arthritis Care Res (Hoboken). 2011; 63: 1729-1735
- Inflammatory myopathies.Mo Med. 2016; 113: 127-130
- Cardiac involvement in adult polymyositis or dermatomyositis: a systematic review.Clin Cardiol. 2012; 35: 686-691
- Cardiac manifestations in dermato-polymyositis.Clin Exp Rheumatol. 1996; 14: 373-379
- Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging.Ann Rheum Dis. 2006; 65: 249-252
- Giant cell myocarditis masquerading as orbital myositis with a rapid, fulminant course necessitating mechanical support and heart transplantation.ESC Heart Fail. 2017; 4: 371-375
- Inflammatory muscle diseases.N Engl J Med. 2015; 372: 1734-1747
- Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases.Medicine (Baltimore). 2004; 83: 35-42
- Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology.Nat Rev Rheumatol. 2020; 16: 155-166
- Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature.Drug Saf. 2018; 41: 919-931
- Chloroquine- and hydroxychloroquine-induced cardiomyopathy: a case report and brief literature review.Am J Clin Pathol. 2021; 155: 793-801
- The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics.Int J Mol Sci. 2021; 22: 2719
- Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial.Circulation. 2003; 107: 3133-3140
- Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases.Eur J Intern Med. 2013; 24: 385-392
- Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH.Eur J Heart Fail. 2002; 4: 559-561
- Molecular mechanism involved in cyclophosphamide-induced cardiotoxicity: Old drug with a new vision.Life Sci. 2019; 218: 112-131
- Role of metabolites of cyclophosphamide in cardiotoxicity.BMC Res Notes. 2017; 10: 406
- Chemotherapy-induced cardiomyopathy.Heart Fail Rev. 2015; 20: 721-730
- Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.Eur Heart J. 2013; 34 (2648a-2648d): 2636-2648
- Consensus best practice pathway of the UK Systemic Sclerosis Study group: management of cardiac disease in systemic sclerosis.Rheumatology (Oxford). 2017; 56: 912-921
- Management of cardiac sarcoidosis in the United States: a Delphi study.Chest. 2012; 141: 154-162
- TNF-alpha inhibition for the treatment of cardiac sarcoidosis.Semin Arthritis Rheum. 2020; 50: 546-552
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
